Immunosuppression Clinical Trial
— MOSAICOfficial title:
Molecular Outcome Surveillance Using AlloSure and AlloMap Guided Immunomodulation in Cardiac Transplant
Verified date | June 2023 |
Source | CareDx |
Contact | Vee Kumar |
Phone | 415-780-2752 |
vkumar[@]caredx.com | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an unblinded, randomized, controlled, two-arm interventional research study enrolling patients who are undergoing heart transplantation. The aim of the study is to determine whether patients at low risk of rejection can safely reduce the doses of their post-transplant immunosuppression medications using a combination of tests that include donor-specific antibodies (DSA), histology (looking at tissue from the donor heart), donor-derived cell-free DNA (AlloSure), and gene expression profiling (AlloMap). Eligible participants will be randomized in a 1:1 ratio into the HeartCare immune-optimization (intervention) arm or the corresponding observational (control) arm. AlloSure and AlloMap are the components of the HeartCare panel developed by CareDx.
Status | Not yet recruiting |
Enrollment | 930 |
Est. completion date | September 2025 |
Est. primary completion date | September 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Heart transplant recipients <2 weeks post-transplant 2. Patients aged 18 years or older 3. Planned post-transplant maintenance immunosuppression regimen consisting of prednisolone, tacrolimus and mycophenolate 4. Female participants of childbearing potential must be willing to ensure that they or their partner use effective contraception during the trial and for 3 months thereafter 5. Participant is willing and able to give informed consent for participation in the trial 6. In the Investigator's opinion, is able and willing to comply with all trial requirements Exclusion Criteria: The participant may not enter the trial if ANY of the following apply: 1. Multi-visceral transplant recipients 2. Female participant who is pregnant, lactating or planning pregnancy during the trial 3. Heart transplant recipients undergoing desensitization protocols prior to transplant based off high immunological risk profiles (determined by treating clinician) 4. Chronic oral steroid use for any reason that cannot be tapered off and discontinued 5. Planned post-transplant immunosuppression regimen utilizing cyclosporine, azathioprine, mTOR inhibitors, and/or co-stimulatory blockers 6. Contraindication to having AlloSure or AlloMap testing 7. Participant with life expectancy of less than 6 months or is inappropriate for immuno-optimization (including those patients at increased risk of primary disease recurrence w/ reduction in post-transplant immunosuppression) 8. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial. This includes clinical events that would significantly impact post-transplant immunosuppression such as major infectious complications or significant rejection episodes within the first month post-transplant. 9. Participants who are currently or have previously participated in another research trial involving an investigational immunological drug in the past 12 weeks 10. Any condition that would preclude protocol biopsies Randomization Criteria (assessed at Week 4) The participant may not proceed with randomization if ANY of the following apply at Week 4 post-transplant: 1. Maintenance immunosuppression that includes cyclosporine, azathioprine, mTOR inhibitors, and/or co-stimulatory blockers 2. Any episodes of biopsy-proven acute rejection (ACR =2R or AMR*) 3. Abnormal molecular profile defined as AlloSure >0.2% 4. Allograft dysfunction defined as LVEF <45% 5. eGFR <30mL/min 6. Presence of DSA (persistence of any pre-transplant DSA or dnDSA) *AMR 1 (H+) with DSA/graft dysfunction or AMR > 2 |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
CareDx |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of Allograft loss at 12-months post-transplant (safety) | Demonstrate the safety and efficacy of HeartCare as a tool to successfully optimize immunosuppressant agents using regular surveillance for safe drug minimization. | 12 months | |
Primary | Incidence of Allograft loss at 24-months post-transplant (safety) | Demonstrate the safety and efficacy of HeartCare as a tool to successfully optimize immunosuppressant agents using regular surveillance for safe drug minimization. | 24 months | |
Primary | Total number of acute rejection episodes (ACR >2R or AMR*) at 12-months post-transplant (safety) | Demonstrate the safety and efficacy of HeartCare as a tool to successfully optimize immunosuppressant agents using regular surveillance for safe drug minimization. | 12 months | |
Primary | Total number of acute rejection episodes (ACR >2R or AMR*) at 24-months post-transplant (safety) | Demonstrate the safety and efficacy of HeartCare as a tool to successfully optimize immunosuppressant agents using regular surveillance for safe drug minimization. | 24 months | |
Primary | EQ-5D survey performed at 12-months post-transplant to assess allograft function (safety) | Demonstrate the safety and efficacy of HeartCare as a tool to successfully optimize immunosuppressant agents using regular surveillance for safe drug minimization. | 12 months | |
Primary | TTE imaging performed at 12-months post-transplant to assess allograft function (safety) | Demonstrate the safety and efficacy of HeartCare as a tool to successfully optimize immunosuppressant agents using regular surveillance for safe drug minimization. | 12 months | |
Primary | EQ-5D survey performed at 24-months post-transplant to assess allograft function (safety) | Demonstrate the safety and efficacy of HeartCare as a tool to successfully optimize immunosuppressant agents using regular surveillance for safe drug minimization. | 24 months | |
Primary | TTE imaging performed at 24-months post-transplant to assess allograft function (safety) | Demonstrate the safety and efficacy of HeartCare as a tool to successfully optimize immunosuppressant agents using regular surveillance for safe drug minimization. | 24 months | |
Primary | Incidence of dnDSA formation at 12-months post-transplant (safety and efficacy) | Demonstrate the safety and efficacy of HeartCare as a tool to successfully optimize immunosuppressant agents using regular surveillance for safe drug minimization. | 12 months | |
Primary | Incidence of dnDSA formation at 24-months post-transplant (safety and efficacy) | Demonstrate the safety and efficacy of HeartCare as a tool to successfully optimize immunosuppressant agents using regular surveillance for safe drug minimization. | 24 months | |
Primary | Change in eGFR at 12-months post-transplant (efficacy) | Demonstrate the safety and efficacy of HeartCare as a tool to successfully optimize immunosuppressant agents using regular surveillance for safe drug minimization. | 12 months | |
Primary | Change in eGFR at 24-months post-transplant (efficacy) | Demonstrate the safety and efficacy of HeartCare as a tool to successfully optimize immunosuppressant agents using regular surveillance for safe drug minimization. | 24 months | |
Primary | Total number of biopsies performed post-transplant, including both surveillance and clinically indicated biopsies (efficacy) | Demonstrate the safety and efficacy of HeartCare as a tool to successfully optimize immunosuppressant agents using regular surveillance for safe drug minimization. | 24 months | |
Secondary | Histological assessment of tissue biopsy with paired AlloSure dd-cfDNA and AlloMap GEP results (HeartCare) - performed both 'For Cause' and 'Surveillance' using standard biopsy assessment. | Identify correlation between HeartCare and histopathological allograft rejection based on all clinical biopsies. | 6 months | |
Secondary | Association between AlloSure dd-cfDNA and AlloMap GEP (HeartCare) results with successful immuno-optimization, longitudinal clinical/laboratory parameters (dnDSA), and histologic data (allograft rejection, CAV). | Establish temporal relationships between HeartCare and allograft injury patterns such as dnDSA formation, allograft rejection and CAV. | 24 months | |
Secondary | Data collection from patient medical record, to capture episodes of infection, viral PCR results, changes in immunosuppression and treatment of rejection, as well as all adverse advents. | Assessment of all medical events throughout the duration of the study. | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05060991 -
Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients
|
Phase 4 | |
Completed |
NCT02833805 -
NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia
|
Phase 2 | |
Completed |
NCT01252537 -
Immunosuppression in HIV-infected Patients With Tuberculosis in Ethiopia
|
N/A | |
Completed |
NCT00621699 -
Pharmacokinetic Drug Interaction Between Ezetimibe and Tacrolimus After Single Dose Administration in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01678937 -
Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents
|
N/A | |
Completed |
NCT00788021 -
Protective Immunity Project 01
|
N/A | |
Active, not recruiting |
NCT00166842 -
Sirolimus Blood Concentrations on Conversion From Oral Solution to Tablets
|
Phase 4 | |
Recruiting |
NCT05616130 -
Pathological Myeloid Activation After Sepsis and Trauma
|
||
Completed |
NCT03117192 -
Zinc Supplementation on Cellular Immunity in Thalassemia Major
|
Phase 4 | |
Recruiting |
NCT01568697 -
Oral Bacteria and Immune System Problems Involved in Gum Disease (Periodontitis)
|
||
Not yet recruiting |
NCT06024226 -
Role of MDSCs and Cancer Stem Cells and Their Cross Talks in NSCLC
|
||
Not yet recruiting |
NCT04961229 -
Booster Dose of COVID-19 Vaccine for Kidney Transplant Recipients Without Adequate Humoral Response
|
Phase 4 | |
Completed |
NCT03139565 -
High Dose vs. Standard Influenza Vaccine in Adult SOT
|
Phase 3 | |
Completed |
NCT02547753 -
Dental Extractions Among Renal Transplant Recipients
|
||
Completed |
NCT01702207 -
Evaluation Of Switching From Twice Daily Tacrolimus To Once Daily Formulation On Cardiovascular Risk
|
Phase 4 | |
Completed |
NCT00626808 -
A Post Marketing Evaluation of the Effectiveness of FluMist Risk Minimization Plan in Children
|
Phase 4 | |
Completed |
NCT00419575 -
Renal Transplantation With Immune Monitoring
|
N/A | |
Completed |
NCT00783380 -
Influenza Vaccination in Immunocompromized Patients
|
Phase 4 | |
Completed |
NCT04835948 -
Efficacy of Single Dose Anti-thymocyte Globulin in the Modulation of T Lymphocytes in Kidney Transplantation
|
||
Recruiting |
NCT05043870 -
Combined Immunosuppression for Pediatric Crohn's Disease
|
Phase 4 |